Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers - PubMed (original) (raw)
Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers
B V Zlokovic et al. Proc Natl Acad Sci U S A. 1996.
Abstract
A soluble form of Alzheimer disease amyloid beta-protein (sA beta) is transported in the blood and cerebrospinal fluid mainly complexed with apolipoprotein J (apoJ). Using a well-characterized in situ perfused guinea pig brain model, we recently obtained preliminary evidence that apoJ facilitates transport of sA beta (1-40)-apoJ complexes across the blood-brain barrier and the blood-cerebrospinal fluid barrier, but the mechanisms remain poorly understood. In the present study, we examined the transport process in greater detail and investigated the possible role of glycoprotein 330 (gp330)/megalin, a receptor for multiple ligands, including apoJ. High-affinity transport systems with a Km of 0.2 and 0.5 nM were demonstrated for apoJ at the blood-brain barrier and the choroid epithelium in vivo, suggesting a specific receptor-mediated mechanism. The sA beta (1-40)-apoJ complex shared the same transport mechanism and exhibited 2.4- to 10.2-fold higher affinity than apoJ itself. Binding to microvessels, transport into brain parenchyma, and choroidal uptake of both apoJ and sA beta (1-40)-apoJ complexes were markedly inhibited (74-99%) in the presence of a monoclonal antibody to gp330/megalin and were virtually abolished by perfusion with the receptor-associated protein, which blocks binding of all known ligands to gp330. Western blot analysis of cerebral microvessels with the monoclonal antibody to gp330 revealed a protein with a mass identical to that in extracts of kidney membranes enriched with gp330/megalin, but in much lower concentration. The findings suggest that gp330/megalin mediates cellular uptake and transport of apoJ and sA beta (1-40)-apoJ complex at the cerebral vascular endothelium and choroid epithelium.
Similar articles
- Glycoprotein 330/megalin (LRP-2) has low prevalence as mRNA and protein in brain microvessels and choroid plexus.
Chun JT, Wang L, Pasinetti GM, Finch CE, Zlokovic BV. Chun JT, et al. Exp Neurol. 1999 May;157(1):194-201. doi: 10.1006/exnr.1999.7052. Exp Neurol. 1999. PMID: 10222122 - Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin.
Kounnas MZ, Loukinova EB, Stefansson S, Harmony JA, Brewer BH, Strickland DK, Argraves WS. Kounnas MZ, et al. J Biol Chem. 1995 Jun 2;270(22):13070-5. doi: 10.1074/jbc.270.22.13070. J Biol Chem. 1995. PMID: 7768901 - Apolipoprotein J (clusterin) and Alzheimer's disease.
Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J. Calero M, et al. Microsc Res Tech. 2000 Aug 15;50(4):305-15. doi: 10.1002/1097-0029(20000815)50:4<305::AID-JEMT10>3.0.CO;2-L. Microsc Res Tech. 2000. PMID: 10936885 Review.
Cited by
- Cryo-EM structures elucidate the multiligand receptor nature of megalin.
Goto S, Tsutsumi A, Lee Y, Hosojima M, Kabasawa H, Komochi K, Nagatoishi S, Takemoto K, Tsumoto K, Nishizawa T, Kikkawa M, Saito A. Goto S, et al. Proc Natl Acad Sci U S A. 2024 May 28;121(22):e2318859121. doi: 10.1073/pnas.2318859121. Epub 2024 May 21. Proc Natl Acad Sci U S A. 2024. PMID: 38771880 - Clusterin is a Potential Therapeutic Target in Alzheimer's Disease.
Palihati N, Tang Y, Yin Y, Yu D, Liu G, Quan Z, Ni J, Yan Y, Qing H. Palihati N, et al. Mol Neurobiol. 2024 Jul;61(7):3836-3850. doi: 10.1007/s12035-023-03801-1. Epub 2023 Nov 29. Mol Neurobiol. 2024. PMID: 38017342 Review. - An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele.
Meuret CJ, Hu Y, Smadi S, Bantugan MA, Xian H, Martinez AE, Krauss RM, Ma QL, Nedelkov D, Yassine HN. Meuret CJ, et al. Alzheimers Res Ther. 2023 May 23;15(1):96. doi: 10.1186/s13195-023-01239-0. Alzheimers Res Ther. 2023. PMID: 37221560 Free PMC article. - Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology.
Bellaver B, Puig-Pijoan A, Ferrari-Souza JP, Leffa DT, Lussier FZ, Ferreira PCL, Tissot C, Povala G, Therriault J, Benedet AL, Ashton NJ, Servaes S, Chamoun M, Stevenson J, Rahmouni N, Vermeiren M, Macedo AC, Fernández-Lebrero A, García-Escobar G, Navalpotro-Gómez I, Lopez O, Tudorascu DL, Cohen A, Villemagne VL, Klunk WE, Gauthier S, Zimmer ER, Karikari TK, Blennow K, Zetterberg H, Suárez-Calvet M, Rosa-Neto P, Pascoal TA. Bellaver B, et al. Alzheimers Dement. 2023 Sep;19(9):3815-3825. doi: 10.1002/alz.13014. Epub 2023 Mar 15. Alzheimers Dement. 2023. PMID: 36919582 Free PMC article. - Structures of LRP2 reveal a molecular machine for endocytosis.
Beenken A, Cerutti G, Brasch J, Guo Y, Sheng Z, Erdjument-Bromage H, Aziz Z, Robbins-Juarez SY, Chavez EY, Ahlsen G, Katsamba PS, Neubert TA, Fitzpatrick AWP, Barasch J, Shapiro L. Beenken A, et al. Cell. 2023 Feb 16;186(4):821-836.e13. doi: 10.1016/j.cell.2023.01.016. Epub 2023 Feb 6. Cell. 2023. PMID: 36750096 Free PMC article.
References
- J Exp Med. 1983 Feb 1;157(2):667-86 - PubMed
- Pharm Res. 1995 Oct;12(10):1395-406 - PubMed
- J Clin Invest. 1987 Jun;79(6):1798-811 - PubMed
- J Exp Med. 1987 Jul 1;166(1):109-28 - PubMed
- Am J Pathol. 1987 Oct;129(1):183-91 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous